CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

Status Completed

Clinical Trial Summary

The objective of this study was to compare the safety, efficacy, and tolerability of two different dose levels of CyclASol Ophthalmic Solutions to placebo (vehicle) and Restasis for the treatment of the signs and symptoms of Dry Eye Disease (DED).

Clinical Trial Description

This phase 2 study explored the safety, efficacy and tolerability of two CyclASol concentrations as one drop twice daily versus vehicle (placebo). In addition to the masked vehicle control arm, an open-label comparator arm consisting of Restasis was included.

The study explored a range of signs and symptoms of DED to gain an understanding of the possible treatment effects in comparison to vehicle and estimation of effect sizes. In line with current treatment guidelines, the proposed phase 2 population consisted of patients suffering from moderate to severe DED.

The primary treatment comparisons in this study were between the two CyclASol concentrations versus vehicle for the sign variable total corneal fluorescein staining and the symptom variable dryness severity visual analogue scale at day 113. All other comparisons between treatments groups were considered secondary analyses. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02617667
Study type	Interventional
Source	Novaliq GmbH
Contact
Status	Completed
Phase	Phase 2
Start date	January 2016
Completion date	September 2016

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04425551` - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction	N/A
Not yet recruiting	`NCT06379685` - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.	Phase 1
Recruiting	`NCT04701086` - 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis	N/A
Active, not recruiting	`NCT03697876` - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel	Phase 1
Terminated	`NCT02815293` - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye	Phase 3
Completed	`NCT02910713` - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation	N/A
Completed	`NCT04104997` - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers	Phase 1
Recruiting	`NCT02595606` - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients	Phase 4
Completed	`NCT01711424` - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease	N/A
Completed	`NCT01015209` - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers	Phase 1
Completed	`NCT01202747` - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction	Phase 2/Phase 3
Completed	`NCT00969280` - Acupuncture for Dry Eye Syndrome	Phase 3
Completed	`NCT01496482` - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement	N/A
Completed	`NCT00756678` - Efficacy and Acceptability of Two Lubricant Eye Drops	Phase 4
Completed	`NCT00739713` - Effects of Sea Buckthorn Oil on Dry Eye	N/A
Completed	`NCT00370747` - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome	Phase 2
Completed	`NCT00349440` - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy	Phase 4
Completed	`NCT05162261` - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction	N/A
Completed	`NCT02871440` - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye	Phase 3
Completed	`NCT05042960` - Computer Screen Properties Study	N/A